Week-24 safety of fostemsavir in heavily treatment-experienced participants with HIV-1 (Study 205888, formerly AI438-047)

被引：0
|
作者：
Kozal, M. [1 ]
Aberg, J. [2 ]
Pialoux, G. [3 ]
Cahn, P. [4 ]
Thompson, M. [5 ]
Molina, J-M [6 ]
Grinsztejn, B. [7 ]
Diaz, R. [8 ]
Lazzarin, A. [9 ]
Gummel, M. [10 ]
Pierce, A. [11 ]
Ackerman, P. [12 ]
Llamoso, C. [12 ]
Lataillade, M. [12 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Hop Tenon, Paris, France
[4] Fdn Huesped, Buenos Aires, DF, Argentina
[5] AIDS Res Consortium Atlanta, Atlanta, GA USA
[6] Hop St Louis, Paris, France
[7] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil
[8] Univ Fed Sao Paulo, Sao Paulo, Brazil
[9] Osped San Raffaele, Milan, Italy
[10] GlaxoSmithKline, Upper Providence, PA USA
[11] ViiV Healthcare, Res Triangle Pk, NC USA
[12] ViiV Healthcare, Branford, CT USA
来源：
HIV MEDICINE | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P31
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [1] Phase 3 study of fostemsavir in heavily treatment experienced HIV-1 infected subjects: day 8 and week 24 primary efficacy and safety results (Study 205888, formerly AI438-047)
    Kozal, M.
    Aberg, J.
    Pialoux, G.
    Cahn, P.
    Thompson, M.
    Molina, J-M
    Grinsztejn, B.
    Diaz, R.
    Lazzarin, A.
    Gummel, M.
    Pierce, A.
    Ackerman, P.
    Llamoso, C.
    Lataillade, M.
    HIV MEDICINE, 2018, 19 : S27 - S27
  • [2] Week 48 safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants (BRIGHTE study)
    Aberg, J.
    Molina, J.
    Kozal, M.
    Cahn, P.
    Lalezari, J.
    Thompson, M.
    Diaz, R.
    Castagna, A.
    Pialoux, G.
    Gummel, M.
    Pierce, A.
    Ackerman, P.
    Llamoso, C.
    Lataillade, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [3] Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1
    Anderson, Sarah-Jane
    van Doornewaard, Alexander
    Turner, Matthew
    Jacob, Ian
    Clark, Andrew
    Browning, Dominy
    Schroeder, Melanie
    CLINICAL THERAPEUTICS, 2022, 44 (06) : 886 - 900
  • [4] Phase III study of fostemsavir in heavily treatment-experienced HIV-1 infected participants: BRIGHTE Week 48 subgroup analysis in randomised cohort participants
    Molina, J.
    Aberg, J.
    Cassetti, I.
    Kozal, M.
    Latiff, G.
    Lalezari, J.
    Pialoux, G.
    Streinu-Cercel, A.
    Gummel, M.
    Pierce, A.
    Ackerman, P.
    Llamoso, C.
    Lataillade, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [5] Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
    Aberg, Judith A.
    Shepherd, Bronagh
    Wang, Marcia
    Madruga, Jose V.
    Mendo Urbina, Fernando
    Katlama, Christine
    Schrader, Shannon
    Eron, Joseph J.
    Kumar, Princy N.
    Sprinz, Eduardo
    Gartland, Margaret
    Chabria, Shiven
    Clark, Andrew
    Pierce, Amy
    Lataillade, Max
    Tenorio, Allan R.
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (09) : 2321 - 2335
  • [6] Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
    Judith A. Aberg
    Bronagh Shepherd
    Marcia Wang
    Jose V. Madruga
    Fernando Mendo Urbina
    Christine Katlama
    Shannon Schrader
    Joseph J. Eron
    Princy N. Kumar
    Eduardo Sprinz
    Margaret Gartland
    Shiven Chabria
    Andrew Clark
    Amy Pierce
    Max Lataillade
    Allan R. Tenorio
    Infectious Diseases and Therapy, 2023, 12 : 2321 - 2335
  • [7] Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHTE study)
    Lataillade, M.
    Lalezari, J.
    Aberg, J.
    Molina, J-M.
    Kozal, M.
    Cahn, P.
    Thompson, M.
    Diaz, R.
    Castagna, A.
    Gummel, M.
    Gartland, M.
    Pierce, A.
    Ackerman, P.
    Llamoso, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 1 - 2
  • [8] Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
    Lataillade, Max
    Lalezari, Jacob P.
    Kozal, Michael
    Aberg, Judith A.
    Pialoux, Gilles
    Cahn, Pedro
    Thompson, Melanie
    Molina, Jean-Michel
    Moreno, Santiago
    Grinsztejn, Beatriz
    Diaz, Ricardo S.
    Castagna, Antonella
    Kumar, Princy N.
    Latiff, Gulam H.
    De Jesus, Edwin
    Wang, Marcia
    Chabria, Shiven
    Gartland, Margaret
    Pierce, Amy
    Ackerman, Peter
    Llamoso, Cyril
    LANCET HIV, 2020, 7 (11): : E740 - E751
  • [9] Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
    Ackerman, Peter
    Thompson, Melanie
    Molina, Jean-Michel
    Aberg, Judith
    Cassetti, Isabel
    Kozal, Michael
    Castagna, Antonella
    Martins, Marcelo
    Ramgopal, Moti
    Sprinz, Eduardo
    Trevino-Perez, Sandra
    Streinu-Cercel, Adrian
    Latiff, Gulam H.
    Pialoux, Gilles
    Kumar, Princy N.
    Wang, Marcia
    Chabria, Shiven
    Pierce, Amy
    Llamoso, Cyril
    Lataillade, Max
    AIDS, 2021, 35 (07) : 1061 - 1072
  • [10] Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1: week 240 results of the phase III BRIGHTE study
    Aberg, J.
    Shepherd, B.
    Wang, M.
    Madruga, J.
    Mendo Urbina, F.
    Katlama, C.
    Schrader, S.
    Eron, J.
    Chabria, S.
    Clark, A.
    Pierce, A.
    Lataillade, M.
    Ackerman, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 63 - 64
12345